Company overview
Biognosys provides next-generation mass spectrometry-based proteomics contract research services to accelerate pharma and biotech drug discovery, development, and clinical trials. Key offerings include unbiased protein expression profiling from tissues and biofluids, drug target identification and validation, biomarker discovery, and custom panels for absolute quantification using proprietary HRM-MS and PQ500 technologies. They have expanded into multiomics with biocrates metabolomics and lipidomics services available in Europe and the US.
Biognosys is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services, Diagnostics & Testing partner serving United States & Americas. Core focus areas include proteomics services, mass spectrometry, biomarker discovery, drug target identification, multiomics cro.
Industry categories: CRO & Clinical Services, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Biognosys include Cro, Mass Spectrometry — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://biognosys.com
- Categories
- CRO & Clinical Services, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- proteomics services, mass spectrometry, biomarker discovery, drug target identification, multiomics cro
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What proteomics technologies does Biognosys offer?
- Biognosys offers HRM-MS for high-content protein quantification, LiP-MS for drug target deconvolution, PQ500 reference peptides for plasma proteomics, and P2-iST for deep plasma proteome analysis identifying nearly 6,000 proteins.
- What services support drug development stages?
- Services cover target discovery and validation, mechanism of action studies, biomarker discovery in tissues and biofluids, and clinical proteomics across all research phases to de-risk drug R&D.
- Where are Biognosys services available?
- Proteomics and expanded multiomics services including metabolomics and lipidomics are offered from laboratories in Europe and the US near Boston.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
